New Millennium Group LLC Grows Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

New Millennium Group LLC lifted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 3.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 214,309 shares of the biotechnology company’s stock after acquiring an additional 7,246 shares during the quarter. ADMA Biologics makes up about 2.1% of New Millennium Group LLC’s holdings, making the stock its 14th largest holding. New Millennium Group LLC’s holdings in ADMA Biologics were worth $3,675,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. USA Financial Formulas boosted its holdings in shares of ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 539 shares in the last quarter. Vontobel Holding Ltd. grew its holdings in ADMA Biologics by 7.0% in the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 888 shares during the last quarter. GAMMA Investing LLC increased its position in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at $30,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in ADMA Biologics by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after buying an additional 1,509 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

ADMA opened at $16.15 on Friday. The firm’s fifty day simple moving average is $18.10 and its two-hundred day simple moving average is $17.55. ADMA Biologics, Inc. has a 52-week low of $5.02 and a 52-week high of $23.64. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 57.68 and a beta of 0.76. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the previous year, the firm posted $0.01 EPS. Equities analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Brad L. Tade sold 15,000 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have commented on ADMA. HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James raised their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.